Hormonal
Diet-induced obesity promotes tumor growth and progression in breast and prostate cancer models, whereas calorie restriction (CR) slows tumor growth and increases tumor latency.
Maintaining a healthy weight and avoiding adult weight gain are critical for reducing the risk of aggressive cancer and improving survival outcomes. While weight loss is challenging, even modest weight loss (e.g., 10%) can positively impact biomarkers associated with breast cancer. Focus on sustainable lifestyle changes rather than rapid weight loss.
diet-induced obesity has been demonstrated to drive tumor growth in a variety of mouse models with both luminal... and basal-like tumor characteristics... diet-induced obesity reduced tumor latency in the Hi-Myc mouse model... and promoted tumor progression in a transgenic mouse model with PTEN haploinsufficiency... CR slows tumor growth in mouse models regardless of tumor subtype... CR slowed progression to adenocarcinoma in the Hi-Myc transgenic mouse model of prostate cancer... CR has also been demonstrated to impact tumor growth in the TRAMP model
Why this rating
Strong support from multiple preclinical mouse models and consistent epidemiologic associations, though human clinical trials on weight loss and mortality are noted as limited.
Source
Obesity and cancer: mechanistic insights from transdisciplinary studies
Emma H. Allott et al. · Endocrine Related Cancer · 2015
DOI 10.1530/erc-15-0400
More from this paper
- Obesity is associated with delayed cancer diagnosis and reduced treatment efficacy due to screening biases, technical challenges, and altered drug metabolism.Good
- Metformin use is associated with reduced cancer incidence and mortality in diabetic patients, with specific benefits observed in HER2-positive breast cancer and prostate cancer recurrence.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →